Post-tamoxifen use of Femara available in Korea

Novartis Korea said on November 4 that the Korea Food and Drug Administration has approved an extended adjuvant treatment with Femara (letrozole) in postmenopausal women with early breast cancer who had completed fiver years of therapy with tamoxifen.

Ealier, Novatis Headquarters announced that its supplementary New Drug Application for Femara had been granted priority review by the U.S. Foo...